Streetbeat News

Stock Prices

AZN

AstraZeneca has raised its 2024 guidance, now expecting total revenue and core EPS to increase by a mid-teens percentage, up from the previously anticipated low double-digit to low-teens percentage. This is due to strong growth in product sales and alliance revenue.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 6:34 am

AZN

AstraZeneca (NASDAQ:AZN) reported Q2 adjusted EPS of $0.99, missing the $1.20 estimate, but sales of $12.98B beat the $12.75B estimate. EPS decreased by 7.91% YoY, while sales increased by 13.73% YoY.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 6:28 am

INDV

Indivior PLC has announced a new $100 million share repurchase program, expected to be completed within six months. The program aims to repurchase Indivior's ordinary shares and is set to be completed by the end of July.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 6:13 am

INDV

Indivior (NASDAQ:INDV) reported Q2 earnings per share of $0.44, significantly beating the analyst estimate of $0.14. The company also reported sales of $299 million, surpassing the $296.05 million estimate. Both earnings and sales showed year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 6:09 am

BABA

JD

PDD

China's central bank, the PBOC, has conducted an unscheduled lending operation, issuing 200 billion yuan in one-year loans at a reduced rate of 2.30%. This move aims to support the economy amid deflationary pressures and weak consumer demand. The U.S. Federal Reserve is likely to hold rates steady at the upcoming FOMC meeting.

Portfolio Pulse from Benzinga Neuro

July 25, 2024 | 6:01 am

STLA

Stellantis (NYSE:STLA) reported a significant decline in its half-year earnings and sales. The company's EPS dropped by 31.9% to $2.54 from $3.73 YoY, and sales decreased by 14.63% to $91.53 billion from $107.21 billion YoY.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 5:58 am

SNY

TEVA

Teva and Sanofi have accelerated the enrollment for their Phase 2b trial of duvakitug (anti-TL1A) for treating inflammatory bowel disease (IBD), with topline results now expected in Q4 2024. This collaboration aims to develop and commercialize the treatment for moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD).

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 5:47 am

SNY

Sanofi has upgraded its 2024 business EPS guidance, now expecting it to be stable at constant exchange rates (CER) instead of a slight decrease. However, the currency impact is projected to be between -5.5% to -6.5%.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 5:43 am

CRWD

MSFT

CrowdStrike (NASDAQ: CRWD) experienced a global outage affecting 8.5 million Windows computers due to a faulty update. The company is offering $10 Uber Eats gift cards as an apology, but some users reported issues redeeming them. The incident caused significant disruptions and financial losses, including a $500M hit for Delta Air Lines. Despite this, Ark Invest purchased 20,219 shares of CrowdStrike.

Portfolio Pulse from Benzinga Neuro

July 25, 2024 | 5:11 am

ARGX

argenx (NASDAQ:ARGX) reported Q2 2024 GAAP EPS of $0.45, significantly beating the analyst estimate of $(0.98). The company also reported sales of $489.428 million, surpassing the estimate of $439.217 million. This represents a substantial year-over-year improvement in both earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 5:09 am